Indoco Remedies Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/c2tf8u5d75vm8a0kge6ms8u6.pdf

Key Takeaways


Domestic Formulations: The Acute-Seasonal Hit

Aditi Panandikar: "It is very surprising that when Cyclopam and Cital and the dental portfolio is growing by 30%. So, you have three winners and then you have Febrex Plus, Oxipod and ATL degrew by almost similar percent of a similar value. That has been literally the story of this quarter."

International Formulations: Regulated Markets Lead

Aditi Panandikar: "With this infrastructure, the company can very well go to 4X the kind of topline we are delivering for international."

USFDA: The December Binary

Aditi Panandikar: "I feel pretty confident that our team because the observations might look many in number, but none of them are specifically related to any DI, data integrity, any cleanliness or cleaning validation or any of those major things. Most of them have got to do with the expectation of the agency on how we investigate, how we do certain procedures and processes."

Margins: External Shocks Overwhelm Internal Gains

Aditi Panandikar: "It is very foolish in these times to make any of these comments. For example, all the MMP work we did, which should have resulted in positive, and then one impact of an external environment, it again gets washed out."

Warren: Restructuring and Long Investment Cycles

Aditi Panandikar: "We have many businesses inside Indoco and some of them are really as different as chalk and cheese. So, the OTC business of Warren Remedies and the API manufacturing business of Warren Remedies are very, very different."

FPP and Other Businesses

Aditi Panandikar: "I think we take great pride in the fact that within three years of acquisition, we have been able to turn around FPP."

Guidance & Commitments

CommitmentSpecificsTimeline
USFDA outcome clarityEarliest indication of which way the response goesFirst week of December 2026
Emerging markets recoveryBusiness expected to come to markQ3 FY27
India domestic growthHigh single-digit growthFY27
International growthGood, decent double-digit, if not moreFY27
Europe/UK growth20% plus growth targetNext 1-2 years
Debt repaymentOn track to repay debt for this yearFY27
CAPEXNot more than ₹25 crore this year; bare minimum thereafterFY27 and next year
R&D spendWill not go above 5% of topline (currently 4% YTD)Ongoing
Cash flow conversionWorking to improve OCF to EBITDA conversion back toward 75-90% rangeNo date
US FDA audit for API plantHoping for audit, triggered by own formulation teamBy Q2 next year (hoping)

Key Metrics

MetricQ2 FY27
Consolidated revenue₹506.9 cr, +7.4% YoY; first time crossing ₹500 cr quarterly
Standalone revenue₹438.1 cr, +2% YoY
Consolidated EBITDA margin9.2% at ₹46.4 cr, vs 9.1% YoY and 8.8% QoQ
Standalone EBITDA margin9.2% at ₹40.3 cr, vs 12.4% YoY and 10.3% QoQ
Domestic formulations revenue₹212.8 cr, vs ₹226.1 cr YoY
International formulations revenue₹172 cr, +12.1% YoY
Regulated markets revenue₹110.9 cr, +21.1% YoY
US business revenue₹39.1 cr, +16.4% YoY
Europe revenue₹67.5 cr, +23.5% YoY
Emerging markets revenue₹61.2 cr, vs ₹61.8 cr YoY
API business revenue₹45.1 cr, +4.6% YoY
AnaCipher CRO and Indoco Analytical Solutions revenue₹8.2 cr, +20.8% YoY
Cyclopam brand sales₹206 cr, crossed ₹200 cr threshold
Gastrointestinal portfolio growth30.3% YoY
Stomatological business growth34.8% YoY
Freight cost impact~₹13 cr additional in the quarter
MR productivity (per head yield)₹3.3 lakhs
R&D spend4% of topline on YTD basis
Debt repaid in H1 FY27₹65 cr at consolidated level
Warren toothpaste division revenue~₹36 cr for the quarter